EPICS: Global Perspectives in SCLC (Region 2)
Latest therapeutic developments in SCLC treatment and implications on individualized clinical decision-making. How will emerging data shape future treatment paradigms?
FACULTY CHAIR
Nagashree Seetharamu, MD, MBBS
Donald and Barbara Zucker School of Medicine, Hempstead, NY, USA
Faculty Members
Millie Das, MD
Stanford Cancer Center, Stanford, CA, USA
Sonam Puri, MD
University of Utah, Salt Lake City, UT, USA
Asrar Alahmadi, MBBS
Ohio State University Comprehensive Cancer Center, Columbus, OH, USA
Janakiraman Subramanian, MD
Inova Schar Cancer Institute, Fairfax, VA, USA
Isabel Preeshagul, MD, MS, DO
Memorial Sloan Kettering Cancer Center, New York, NY, USA
Roy Herbst, MD, PhD
Yale Cancer Center, New Haven, CT, USA
Mark Socinski, MD
AdventHealth Cancer Institute, Orlando, FL, USA
REPORT TOPICS INCLUDE
- Standards of Care Across the SCLC Treatment Continuum
- Biomarkers in SCLC
- Recent Progress and Emerging Therapies in Second Line and Beyond
